Agreed. That is the missing link perhaps. If CD12 is not halted, how do we as a company get our drug's effectiveness out there. Perhaps it depends on whether we decide to pay that penalty and release the interim results. We need some sort of external validation beyond the doctors that have issued EINDS as even they have said "we are cautiously optimistic but double blind trials are needed". Hopefully we can release the interim results and show that we are in fact better than the competition so that even if they are approved first, people will still take the chance on us.

As I type this, I am of course thinking "why not try leronlimab...it has no SAEs", but we've all been saying that since the beginning!